Suppr超能文献

单次糖化血红蛋白(A1C)≥6.5%可准确识别非裔美国人中的2型糖尿病/糖耐量受损。

A Single A1C >= 6.5% Accurately Identifies Type 2 Diabetes/Impaired Glucose Tolerance in African Americans.

作者信息

Homko Carol J, Zamora Linda C, Kerper Margaret M, Mozzoli Maria, Kresge Karen, Boden Guenther

机构信息

Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania.

出版信息

J Prim Care Community Health. 2012 Oct 1;3(4):235-8. doi: 10.1177/2150131911435526. Epub 2012 Feb 11.

Abstract

OBJECTIVE

In 2010, the American Diabetes Association revised its criteria for the diagnosis of diabetes to include A1C ≥ 6.5%; however, this has remained controversial, particularly for African Americans. The objective of this pilot study was to examine the usefulness of a single A1C determination in comparison with a same day 2-hour oral glucose tolerance test to diagnose type 2 diabetes in African Americans.

METHODS

In sum, 195 oral glucose tolerance tests and A1Cs were obtained on the same day from 77 overweight and obese African American women and 6 men over a period of 15 months.

RESULTS

A1C ≥ 6.5% was present in 31 of 195 patients, with 15 of these having type 2 diabetes by oral glucose tolerance test, another 12 having impaired glucose tolerance, and 4 having normal glucose tolerance. This gives a sensitivity of 50% and a specificity of 90%, with a positive predictive value of 48% and a negative predictive value of 91%. A1C ≤ 5.6%, proposed by the American Diabetes Association to indicate normal glucose tolerance, was present in only 28 patients, 10 (35.7%) of whom had normal glucose tolerance, whereas 18 (64.3%) had either impaired glucose tolerance (15 patients) or type 2 diabetes (3 patients). Fasting plasma glucose ≥ 126 mg/dL was present in 5 of 29 patients with type 2 diabetes (sensitivity, 17.2%; specificity, 100%).

CONCLUSIONS

First, A1C ≥ 6.5% was a good "rule in" value to identify impaired glucose tolerance and type 2 diabetes (ie, patients at high risk for micro- and macrovascular complications). Second, A1C ≤ 5.6% did not rule out impaired glucose tolerance or type 2 diabetes. Last, fasting plasma glucose ≥ 126 mg/dL detected less than 1 in 5 cases with type 2 diabetes.

摘要

目的

2010年,美国糖尿病协会修订了糖尿病诊断标准,将糖化血红蛋白(A1C)≥6.5%纳入其中;然而,这一标准仍存在争议,尤其是在非裔美国人中。本试点研究的目的是比较单次A1C测定与同日2小时口服葡萄糖耐量试验在诊断非裔美国人2型糖尿病方面的有效性。

方法

在15个月的时间里,从77名超重和肥胖的非裔美国女性及6名男性中,同日获取了195份口服葡萄糖耐量试验和A1C检测结果。

结果

195例患者中有31例A1C≥6.5%,其中15例经口服葡萄糖耐量试验诊断为2型糖尿病,12例为糖耐量受损,4例糖耐量正常。其敏感性为50%,特异性为90%,阳性预测值为48%,阴性预测值为91%。美国糖尿病协会提出的A1C≤5.6%用于表示糖耐量正常,仅28例患者符合此标准,其中10例(35.7%)糖耐量正常,而18例(64.3%)患有糖耐量受损(15例)或2型糖尿病(3例)。29例2型糖尿病患者中有5例空腹血糖≥126mg/dL(敏感性为17.2%,特异性为100%)。

结论

首先,A1C≥6.5%是识别糖耐量受损和2型糖尿病(即微血管和大血管并发症高危患者)的良好“纳入”值。其次,A1C≤5.6%不能排除糖耐量受损或2型糖尿病。最后,空腹血糖≥126mg/dL在2型糖尿病患者中检出率不到五分之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验